Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...

The Phase I trial of the combination therapy saw a an approximate 66% rate of near-complete remission in its cohort of breast ...

As more companies are investigating radiopharmaceuticals, the complexities and red tape faced by sponsors are becoming more ...

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and ...

As the first cohort of patients are dosed in the Phase II trial, multiple new trial sites are added for the glioblastoma ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

AstraZeneca has reported positive results from a Phase III trial that evaluated Truqap combined with abiraterone and ADT for ...

The Global Coalition for Adaptive Research (GCAR) has executed an agreement to evaluate AstraZeneca's AZD1390 in the GBM ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...

MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.